Authors:
GARCIADELMURO X
VADELL C
MANGA GP
BOVER I
RIFA J
BELTRAN M
BARROS MM
GERMA JR
FABREGAT X
MORENO V
SALVADOR A
VILADIU P
Citation: X. Garciadelmuro et al., RANDOMIZED DOUBLE-BLIND-STUDY COMPARING TROPISETRON ALONE AND IN COMBINATION WITH DEXAMETHASONE IN THE PREVENTION OF ACUTE AND DELAYED CISPLATIN-INDUCED EMESIS, European journal of cancer, 34(1), 1998, pp. 193-195
Authors:
VADELL C
SEGUI MA
GIMENEZARNAU JM
MORALES S
CIRERA L
BESTIT I
BATISTE E
BLANCO R
JOLIS L
BOLEDA M
ANTON I
Citation: C. Vadell et al., ANTICACHECTIC EFFICACY OF MEGESTROL-ACETATE AT DIFFERENT DOSES AND VERSUS PLACEBO IN PATIENTS WITH NEOPLASTIC CACHEXIA, American journal of clinical oncology, 21(4), 1998, pp. 347-351
Authors:
GRAUS F
DALMAU J
RENE R
TORA M
MALATS N
VERSCHUUREN JJ
CARDENAL F
VINOLAS N
DELMURO JG
VADELL C
MASON WP
ROSELL R
POSNER JB
REAL FX
Citation: F. Graus et al., ANTI-HU ANTIBODIES IN PATIENTS WITH SMALL-CELL LUNG-CANCER - ASSOCIATION WITH COMPLETE RESPONSE TO THERAPY AND IMPROVED SURVIVAL, Journal of clinical oncology, 15(8), 1997, pp. 2866-2872
Authors:
MOYSSET I
LLORETA J
MIGUEL A
VADELL C
RIBALTA T
ESTRACH T
SERRANO S
Citation: I. Moysset et al., THYMOMA ASSOCIATED WITH CD4-INFECTION, AND KAPOSIS-SARCOMA( LYMPHOPENIA, CYTOMEGALOVIRUS), Human pathology, 28(10), 1997, pp. 1211-1213
Authors:
ROSELL R
LI SR
ANTON A
MORENO I
MARTINEZ E
VADELL C
MATE JL
ARIZA A
MONZO M
FONT A
MOLINA F
DEANTA JM
PIFARRE A
Citation: R. Rosell et al., PROGNOSTIC VALUE OF K-RAS 12 GENOTYPES IN PATIENTS WITH ADVANCED NONSMALL CELL LUNG-CANCER RECEIVING CARBOPLATIN WITH EITHER INTRAVENOUS ORCHRONIC ORAL DOSE ETOPOSIDE, International journal of oncology, 5(2), 1994, pp. 169-176
Citation: J. Lloreta et al., FIBROLAMELLAR HEPATIC TUMOR WITH NEUROSECRETORY FEATURES AND SYSTEMICDEPOSITION OF AA AMYLOID, Ultrastructural pathology, 18(1-2), 1994, pp. 287-292
Authors:
ROSELL R
GOMEZCODINA J
ANTON A
SANCHEZ JJ
VADELL C
Citation: R. Rosell et al., ESCALATING HIGH-DOSE EPIRUBICIN PLUS CISPLATIN IN SMALL-CELL LUNG-CANCER WITH GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR USE WHEN APPROPRIATE, Seminars in oncology, 21(1), 1994, pp. 48-53